Table 3 Comparison of tacrolimus (TAC) and cyclosporine A (CsA) concentration in blood and its dosing between genotypes of CTLA4 +49A>G polymorphism (rs231775) in patients receiving the drug every 12 and 24 h (CsA-12 h, n = 183), (TAC-12 h, n = 53), (TAC-24 h, n = 156).

From: Influence of TGFB1 and CTLA4 polymorphisms on calcineurin inhibitors dose and risk of acute rejection in renal transplantation

Parameter

Genotype

Mean ± SD

95% CI

Min

Max

P

+49A>G CTLA4 (CsA = 12 h)

CsA blood concentration (ng/mL)

AA

114.81 ± 50.95

101.53–128.09

58.8

262.9

0.962

AG

114.11 ± 48.34

103.99–124.24

60.7

315.9

GG

116.84 ± 46.16

100.73–132.95

53.2

215.5

CsA dose (mg/day)

AA

162.62 ± 64.94

145.70–179.55

50

500

0.386

AG

176.66 ± 60.40

164.01–189.31

50

400

GG

169.85 ± 53.92

151.03–188.66

100

400

Concentration/dose of CsA (C/D)

AA

0.74 ± 0.32

0.66–0.83

0.02

1.75

0.320

AG

0.67 ± 0.25

0.62–0.72

0.01

1.57

GG

0.71 ± 0.27

0.61–0.80

0.34

1.4

+49A>G CTLA4 (TAC = 12 h)

TAC blood concentration (ng/mL)

AA

7.27 ± 2.46

6.05–8.50

3.1

11.3

0.394

AG

6.69 ± 3.87

5.13–8.26

2.1

22.4

GG

5.48 ± 1.83

4.07–6.90

2.9

8

TAC dose (mg/day)

AA

4.83 ± 3.18

3.24–6.41

2

14

0.548

AG

5.59 ± 4.84

3.63–7.55

1.5

24

GG

3.88 ± 3.37

1.29–6.47

1

12

Concentration/dose of TAC (C/D)

AA

1.95 ± 1.16

1.37–2.53

0.57

4.9

0.778

AG

1.74 ± 1.03

1.32–2.16

0.25

3.73

GG

1.93 ± 0.82

1.30–2.56

0.51

2.9

+49A>G CTLA4 (TAC = 24 h)

TAC blood concentration (ng/mL)

AA

5.63 ± 2.60

4.88–6.39

2

16.6

0.527

AG

5.50 ± 2.17

5.01–5.99

2.1

15.1

GG

6.08 ± 2.53

5.13–7.02

2.1

11.5

TAC dose (mg/day)

AA

3.30 ± 1.72

2.80–3.80

1

8

0.605

AG

3.04 ± 2.03

2.58–3.50

1

12

GG

3.4 ± 1.69

2.76–4.03

1

8

Concentration/dose of TAC (C/D)

AA

2.11 ± 1.35

1.72–2.51

0.58

6.4

0.201

AG

2.58 ± 1.98

2.13–3.03

0.54

9.5

GG

2.07 ± 1.14

1.64–2.50

0.55

5.6

Back to article page